Unichem’s U.S. Unit Voluntarily Recalls Buspirone Tablets on Quality Deviation

Unichem Laboratories Limited ( (IN:UNICHEMLAB) ) just unveiled an announcement.

Unichem Pharmaceuticals (USA), Inc., the U.S. arm of Unichem Laboratories, has initiated a voluntary recall of certain lots of Buspirone Hydrochloride Tablets, USP, 5 mg in 500-count bottles distributed in the U.S. market. The recall was triggered by an out-of-specification assay result detected at the 12‑month long‑term stability checkpoint, although no adverse events have been reported so far.

The action underscores the company’s stated focus on quality control and patient safety, as it proactively removes potentially non‑compliant product from the market. While the scale of financial impact is not disclosed, the recall highlights both the operational scrutiny generic drug makers face in the U.S. and Unichem’s willingness to act pre‑emptively to maintain regulatory and stakeholder confidence.

More about Unichem Laboratories Limited

Unichem Laboratories Limited, through its wholly owned U.S. subsidiary Unichem Pharmaceuticals (USA), Inc., operates in the pharmaceutical industry, focusing on the development, manufacturing and distribution of generic medicines. The company supplies regulated markets such as the United States, emphasizing product quality and patient safety across its manufacturing and supply chain operations.

Average Trading Volume: 4,589

Technical Sentiment Signal: Sell

Current Market Cap: 23.89B INR

For detailed information about UNICHEMLAB stock, go to TipRanks’ Stock Analysis page.